Last edition
News about "Mark Rutstein"
Novartis Reports Strong Long-Term Efficacy of Scemblix in Chronic Myeloid Leukemia Trial
Novartis’ Scemblix demonstrated sustained efficacy and a favourable safety profile over nearly three years of follow-up, reinforcing its potential as a frontline treatment option for adults with Philadelphia chromosome-positive chronic myeloid leukemia.
Mark Rutstein | 03/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members